Abstract:
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17ß-hydroxysteroid dehydrogenase (17ß-HSD) such as 17ß-HSD type 1, type 2 or type 3 enzyme.
Abstract:
This invention relates to novel substituted thiophenepyrimidinone derivatives and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorder, such as steroid hormone dependent diseases or disorders requiring inhibition of 17&bgr;-hydroxysteroid dehydrogenase enzymes.
Abstract:
The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17.beta.-hydroxysteroid dehydrogenase type I (17.beta.-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17.beta.-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17.beta.-estradiol concentration.
Abstract:
This invention relates to novel estratrien-triazoles of general formula ( I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone depend ent disease or disorder requiring the inhibition of a 17.beta.-hydroxysteroi d dehydrogenase (17.beta.-HSD) such as 17.beta.-HSD type 1, type 2 or type 3 enzyme.
Abstract:
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17&bgr;-hydroxysteroid dehydrogenase (17&bgr;-HSD) such as 17&bgr;-HSD type 1, type 2 or type 3 enzyme.